Phase 1/2 study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Trial Profile

Phase 1/2 study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Enzastaurin; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2010 Actual end ate added as Dec 2009 reported by as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top